

Special Issue

Diagnosis, Treatment and Prognosis of Cardiovascular Diseases 2.0

Message from the Guest Editor

We are pleased to announce the launch of a new Special Issue, "Diagnosis, Treatment and Prognosis of Cardiovascular Diseases 2.0", a continuation of a previously successful Special Issue.

Given the success of the first edition comprising 22 high-quality articles, the second edition of the Special Issue aims to continue the publication of original articles, reviews, meta-analyses and letters related to the burden of cardiovascular diseases worldwide.

This Special Issue's second edition aims to explore these complicated and stimulating aspects by focusing on:

- i) Innovative diagnostic tools;
- ii) The identification of risk factors and indices of diseases and prognoses;
- iii) Risk stratification and cardiovascular prevention;
- iv) Drug and nondrug therapies;
- v) Pathophysiology and the phenotypic expression of cardiovascular diseases;
- vi) The mapping of individuals' susceptibilities to cardiovascular diseases;
- ii) Cardiovascular rehabilitation;
- viii) Clinical and health management models, with particular attention paid to the transfer of guideline indications into the real world.

Guest Editor

Dr. Laura Adelaide Dalla Vecchia
IRCCS Istituti Clinici Scientifici Maugeri, Milan, Italy

Deadline for manuscript submissions

closed (5 September 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/147132

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).